Drug intelligence / Profile preview

PC-300

Development stage
Unknown
Lead developer
Ciprés Grupo Médico
Administration
Oral
01

Overview

PC-300 is a herbal medicinal formulation administered as a tea, composed of a combination of *Eryngium heterophyllum* (commonly known as Hierba del sapo) and *Amphipterygium adstringens* (commonly known as Cuachalalate). It is primarily investigated in Mexico for its hypolipidemic properties, specifically for the treatment of hypertriglyceridemia and hypercholesterolemia. The formulation leverages the traditional medicinal properties of *Eryngium heterophyllum*, which is noted for its ability to lower serum lipid levels, and *Amphipterygium adstringens*, which is traditionally used for its anti-inflammatory and gastroprotective effects. In clinical settings, PC-300 has been evaluated in comparative studies against conventional fibrate therapies such as bezafibrate, demonstrating significant efficacy in reducing total cholesterol and triglyceride levels when combined with a low-lipid diet.

Brand names
PC-300PC300PC 300
Other names
PC-300 teaPC300 teaPC 300 teaEryngium heterophyllum + Amphipterygium adstringens teaHierba del sapo + Cuachalalate tea

Beyond the preview

Go deeper on PC-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-300.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call